文献速递皮肤肿瘤

咪喹莫特治疗恶性雀斑样痣的疗效

Efficacy of imiquimod in the management of lentigo maligna.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-05-06

这项前瞻性、随机、多中心III期临床研究将283例恶性雀斑样痣患者按1:1随机分配接受咪喹莫特或安慰剂治疗4周,停药4周后行手术切除。咪喹莫特组首次病灶外切除率为92%,安慰剂组为84%,差异无统计学意义(p=0.0743);但咪喹莫特显著缩小了恶性雀斑样痣面积(4.6-3.1 cm2),安慰剂组为(3.9-4.1 cm2)(p<0.001)。结论认为咪喹莫特治疗1个月可缩小恶性雀斑样痣面积,不增加病灶内切除风险,且美学效果良好。

要点

  • 咪喹莫特组首次病灶外切除率92%,安慰剂组84%,差异无统计学意义(p=0.0743)。
  • 咪喹莫特组恶性雀斑样痣面积由4.6降至3.1 cm2,安慰剂组由3.9升至4.1 cm2(p<0.001)。
  • 咪喹莫特治疗1个月可缩小恶性雀斑样痣面积,不增加病灶内切除风险,美学效果良好。

核心结论

  • 咪喹莫特治疗1个月可缩小恶性雀斑样痣面积,不增加病灶内切除风险,且美学效果良好。

研究设计与样本

  • 前瞻性、随机、多中心III期临床研究,283例患者参与,改良意向治疗人群247例(安慰剂组121例,咪喹莫特组126例)。
  • 患者按1:1随机分配接受咪喹莫特或安慰剂治疗4周,末次用药4周后行恶性雀斑样痣切除。
  • 主要终点为距残余色素5 mm边界的病灶外切除;次要终点包括两组切除面积的增益、获得病灶外切除所需的修正手术次数、无复发生存时间及治疗后完全缓解例数。

主要发现

  • 首次病灶外切除在咪喹莫特组116例(92%)中进行,安慰剂组102例(84%)中进行,差异无统计学意义(p=0.0743)。
  • 咪喹莫特组恶性雀斑样痣面积由4.6降至3.1 cm2,安慰剂组由3.9升至4.1 cm2,咪喹莫特组缩小面积显著大于安慰剂组(p<0.001)。

临床怎么用

  • 作者认为咪喹莫特治疗1个月可缩小恶性雀斑样痣面积,不增加病灶内切除风险,且美学效果良好。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lentigo maligna (LM) is a melanocytic proliferation occurring on photo-exposed skin that may progress to LM melanoma. Surgery is recommended as first-line treatment. Excision margins of 5-10 mm remain, without international consensus. Several studies have shown that imiquimod, an immunomodulator, induces LM regression. This study investigated the effect of imiquimod versus placebo in neoadjuvant settings. PATIENTS AND METHODS: We performed a prospective, randomized, multicentre, phase III clinical study. Patients were randomly assigned in 1:1 ratio to receive imiquimod or placebo for 4 weeks, followed by LM excision 4 weeks after the last application of imiquimod or placebo. The primary endpoint was extra-lesional excision, with a 5 mm margin from the residual pigmentation after imiquimod or vehicle. Secondary endpoints included the gain on the surface removed between the two groups; number of revision surgeries to obtain extra-lesional excisions; relapse-free time; and number of complete remissions after treatment. RESULTS: A total of 283 patients participated in this study; 247 patients, 121 patients in the placebo group and 126 in the imiquimod group, accounted for the modified ITT population. The first extralesional extirpation was performed in 116 (92%) imiquimod patients and in 102 (84%) placebo patients; the difference was not significant (p = 0.0743). Regarding the surface of LM, imiquimod reduced the LM surface (4.6-3.1 cm2 ) significantly (p < 0.001) more compared to the placebo (3.9-4.1 cm2 ). CONCLUSION: Imiquimod reduces the lentigo maligna surface after 1 month of treatment, without a higher risk of intralesional excision and with a positive aesthetic outcome.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Daude M, Dinulescu M, Nguyen JM, et al. Efficacy of imiquimod in the management of lentigo maligna. J Eur Acad Dermatol Venereol. 2023. PMID: 37114291. doi:10.1111/jdv.19141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。